KLTO
Klotho Neurosciences, Inc.0.3900
+0.0105+2.77%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
28.29MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
8-K
Sells convertible preferred stock
Klotho Neurosciences agreed to sell 3,400 Series C Preferred shares to Sigma9 Capital at $4,400 each on December 2, 2025, convertible into 10,000 common shares per preferred—capped at 9.99% ownership. Closing awaits Certificate of Designation filing by December 31. Deal bolsters cash via Reg D exemption. Nasdaq rules block pre-shareholder approval conversions.
10-Q
Q3 FY2025 results
Klotho Neurosciences narrowed its Q3 operating loss to $1.9M from $2.9M y/y, while YTD operating loss widened to $5.3M from $3.7M amid ramped R&D at $271K (new) and $510K YTD. Net loss hit $2.9M ($0.05/share) versus $3.0M ($0.18/share) y/y, with the gap to operating driven by $1.2M interest on debt conversions; YTD net loss $9.2M ($0.23/share) reflects $3.5M interest versus $4.1M prior. Cash swelled to $7.3M on $11.9M financing—warrant exercises, stock sales, preferred conversions—after $4.6M operating burn; all debt cleared. Shares outstanding ballooned to 70M from 27M year-end. Nasdaq bid price below $1 risks delisting.
8-K
8-K
10-Q
Q2 FY2025 results
Klotho Neurosciences posted a Q2 net loss of $4.1M, up sharply from $0.5M a year ago, driven by $1.9M in operating expenses that quadrupled on higher professional fees, share-based compensation, and initial R&D outlays. Yet financing inflows swelled cash to $8.4M from $64K at year-start, fueled by $11.4M from warrant exercises and $500K each from stock subscriptions and preferred shares. Debt stands at zero after conversions and payoffs. No revenue yet, as the biotech advances its gene therapy platforms. Investors face Nasdaq compliance hurdles.
AIBT
Aibotics Inc.
0.00+0.00
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ANVS
Annovis Bio, Inc.
3.93+0.15
ATHA
Athira Pharma, Inc.
3.88+0.03
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
NGNE
Neurogene Inc.
19.53-0.73